Rashtriya Newsflash

DelveInsight’s, “Paroxysmal Nocturnal Haemoglobinuria Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Paroxysmal Nocturnal Hemoglobinuria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in understanding the Paroxysmal Nocturnal Hemoglobinuria Treatment Landscape @ https://www.delveinsight.com/sample-request/paroxysmal-nocturnal-hemoglobinuria-pipeline-insight

Key Takeaways from the Paroxysmal Nocturnal Hemoglobinuria Pipeline Report

• On May 26, 2026, Regeneron Pharmaceuticals announced a study is researching a treatment combination with two experimental drugs called pozelimab and cemdisiran referred to as “study drugs”. Researchers are looking for a better way to treat Paroxysmal Nocturnal Hemoglobinuria (PNH).
• On May 14, 2026, Hoffmann-La Roche initiated a Phase I/II, first-in-human study consisting of four sequential parts and an open-label extension (OLE). The safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single doses of crovalimab will be evaluated in healthy volunteers (HV) during part 1. The safety, tolerability, PK and PD of multiple doses of crovalimab will be evaluated in participants with paroxysmal nocturnal hemoglobinuria (PNH) in parts 2, 3, 4, and OLE of the study. Efficacy of crovalimab will be evaluated in Parts 2, 3, and 4.
• On May 08, 2026, Novartis Pharmaceuticals conducted a phase 3 study to characterize long-term safety, tolerability and efficacy of iptacopan and to provide access to iptacopan to patients with PNH who have completed Novartis-sponsored Phase 2 or 3 studies with iptacopan.
• DelveInsight’s Paroxysmal Nocturnal Hemoglobinuria pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Paroxysmal Nocturnal Hemoglobinuria treatment.
• The leading Paroxysmal Nocturnal Hemoglobinuria Companies such as Hoffmann-La Roche, Apellis Pharmaceuticals, Regeneron Pharmaceuticals, Biocad, AKARI Therapeutics, Alexion Pharmaceuticals, Novartis Pharmaceuticals, Amgen, BioCryst Pharmaceuticals, MorphoSys, Ra Pharmaceuticals, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Wuhan Createrna Science and Technology, CANbridge, Attune Pharmaceuticals, RallyBio and others.
• Promising Paroxysmal Nocturnal Hemoglobinuria Pipeline Therapies such as HSK39297 tablets, Coversin, MY008211A tablets, Eculizumab Injection, Pegcetacoplan, Crovalimab, Ravulizumab, Iptacopan, LNP023, and others.

Gain in-depth knowledge of key clinical trials, emerging drugs @ Paroxysmal Nocturnal Hemoglobinuria Ongoing Clinical Trials Assessment

Paroxysmal Nocturnal Haemoglobinuria Overview

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired, life-threatening disease of the blood. The disease is characterized by complement-mediated hemolysis with or without hemoglobinuria, an increased susceptibility to thrombotic episodes and/or some degree of bone marrow dysfunction. PNH leads to excessive breakdown of red blood cells, leading to the release of a large amount of haemoglobin into the urine. Symptoms and signs of PNH include: fatigue; dark red/brown urine; difficulty swallowing, abdominal pain, infections, and bruising. The principal studies used to establish the diagnosis of PNH are flow cytometry of peripheral blood and bone marrow analysis. PNH typically starts from the early thirties to the mid‐forties, and often persisting for decades, with a continued dependence on blood transfusions in a proportion of patients. The appropriate treatment for PNH depends on the severity of symptoms. The mainstay of PNH treatment is the drug eculizumab (Soliris).

Paroxysmal Nocturnal Hemoglobinuria Emerging Drugs Profile

• Crovalimab: Hoffman-La-Roche

Crovalimab (RG6107) is a humanised complement inhibitor C5 monoclonal antibody discovered by Chugai using recycling antibody technology. By blocking the cleavage of C5 to C5a and C5b, it is expected to inhibit complement activation, which is the cause of a number of diseases. As the complement system is a key innate immune defense mechanism, we plan to study the potential of this antibody in a broader range of complement-mediated diseases. A phase III clinical trial is evaluating crovalimab for the treatment of paroxysmal nocturnal hemoglobinuria.

• Pozelimab: Regeneron Pharmaceuticals

Pozelimab is an investigational, fully-human monoclonal antibody designed to block complement factor C5 and prevent the destruction of red blood cells (hemolysis) that cause the symptoms of PNH and other diseases mediated by complement pathway activity. It is an IgG4 antibody that binds with high affinity to wild-type and variant human C5 and blocks its activity. Pozelimab was invented using Regeneron’s proprietary VelocImmune technology, which uses a unique genetically-humanized mouse to produce optimized fully-human antibodies. Pozelimab is currently under clinical development, and its safety and efficacy have not been evaluated by any regulatory authority.

The Paroxysmal Nocturnal Hemoglobinuria Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Paroxysmal Nocturnal Hemoglobinuria with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Paroxysmal Nocturnal Hemoglobinuria Treatment.
• Paroxysmal Nocturnal Hemoglobinuria Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Paroxysmal Nocturnal Hemoglobinuria Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Paroxysmal Nocturnal Hemoglobinuria market

Uncover critical updates on therapeutic innovations and their potential impact on patients @ Paroxysmal Nocturnal Hemoglobinuria Unmet Needs

Paroxysmal Nocturnal Hemoglobinuria Companies

Hoffmann-La Roche, Apellis Pharmaceuticals, Regeneron Pharmaceuticals, Biocad, AKARI Therapeutics, Alexion Pharmaceuticals, Novartis Pharmaceuticals, Amgen, BioCryst Pharmaceuticals, MorphoSys, Ra Pharmaceuticals, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Wuhan Createrna Science and Technology, CANbridge, Attune Pharmaceuticals, RallyBio and others.

Paroxysmal Nocturnal Haemoglobinuria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Paroxysmal Nocturnal Hemoglobinuria Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

See the latest progress in drug development and clinical research @ Paroxysmal Nocturnal Hemoglobinuria Market Drivers and Barriers, and Future Perspectives

Scope of the Paroxysmal Nocturnal Hemoglobinuria Pipeline Report

• Coverage- Global
• Paroxysmal Nocturnal Hemoglobinuria Companies- Hoffmann-La Roche, Apellis Pharmaceuticals, Regeneron Pharmaceuticals, Biocad, AKARI Therapeutics, Alexion Pharmaceuticals, Novartis Pharmaceuticals, Amgen, BioCryst Pharmaceuticals, MorphoSys, Ra Pharmaceuticals, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Wuhan Createrna Science and Technology, CANbridge, Attune Pharmaceuticals, RallyBio and others.
• Paroxysmal Nocturnal Hemoglobinuria Pipeline Therapies- HSK39297 tablets, Coversin, MY008211A tablets, Eculizumab Injection, Pegcetacoplan, Crovalimab, Ravulizumab, Iptacopan, LNP023, and others.
• Paroxysmal Nocturnal Hemoglobinuria Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Paroxysmal Nocturnal Hemoglobinuria Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Access the Full Paroxysmal Nocturnal Hemoglobinuria Pipeline Analysis Today! @ Paroxysmal Nocturnal Hemoglobinuria Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. Paroxysmal Nocturnal Hemoglobinuria: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Paroxysmal Nocturnal Hemoglobinuria – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Paroxysmal Nocturnal Hemoglobinuria Collaboration Deals
9. Late Stage Products (Phase III)
10. Crovalimab: Hoffman-La-Roche
11. Mid Stage Products (Phase II)
12. BCX9930: BioCryst Pharmaceuticals
13. Early Stage Products (Phase I)
14. CAN106: CanBridge
15. Inactive Products
16. Paroxysmal Nocturnal Hemoglobinuria Key Companies
17. Paroxysmal Nocturnal Hemoglobinuria Key Products
18. Paroxysmal Nocturnal Hemoglobinuria- Unmet Needs
19. Paroxysmal Nocturnal Hemoglobinuria- Market Drivers and Barriers
20. Paroxysmal Nocturnal Hemoglobinuria- Future Perspectives and Conclusion
21. Paroxysmal Nocturnal Hemoglobinuria Analyst Views
22. Paroxysmal Nocturnal Hemoglobinuria Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/paroxysmal-nocturnal-hemoglobinuria-pipeline-insight